$34.97
8.03% yesterday
Nasdaq, Sep 22, 10:00 pm CET
ISIN
US88322Q1085
Symbol
TGTX

TG Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
13 days ago
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held September 24 - 26, 2025 in Barcelo...
Neutral
GlobeNewsWire
15 days ago
NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has commenced in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy), the company's anti-CD20 monoclonal antibody, in people with relapsing forms of multiple sclerosis (RMS).
Neutral
Seeking Alpha
19 days ago
TG Therapeutics, Inc. (NASDAQ:TGTX ) Cantor Global Healthcare Conference 2025 September 3, 2025 10:20 AM EDT Company Participants Michael Weiss - Chairman, CEO & President Conference Call Participants Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Presentation Prakhar Agrawal Senior Biotech Analyst All right. Welcome, everyone, to day 1 of Cantor's Global Healthcare Conference.
Neutral
GlobeNewsWire
19 days ago
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S.
Neutral
GlobeNewsWire
20 days ago
NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that it has completed its previously authorized $100 million share repurchase program, which was initially announced in August 2024. Under that program, the Company repurchased a total of approximately 3.5 million shares of its common stock at an average price of $28.55 per share.
Neutral
GlobeNewsWire
26 days ago
Fireside chat scheduled for Wednesday, September 3, 2025, at 10:20am ET Fireside chat scheduled for Wednesday, September 3, 2025, at 10:20am ET
Neutral
The Motley Fool
about 2 months ago
TG Therapeutics Q2 Revenue Up 91%
Negative
Investors Business Daily
about 2 months ago
TG Therapeutics stock crashed Monday after the drugmaker reported in-line sales of Briumvi, but missed second-quarter profit expectations.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today